China Medical System Holdings Limited

China Medical System Holdings Limited (CMS) is an investment holding company primarily engaged in the production, marketing, promotion, and sale of pharmaceutical products. Established in 1992, the company operates as a platform linking pharmaceutical innovation and commercialization, dedicated to providing competitive products and services to address unmet healthcare needs. Its principal place of business is located in Hong Kong, with operations extending across China and into Southeast Asia. [5, 6, 9, 13, 16, 18, 19, 21, 23, 27]

CMS focuses on developing and commercializing innovative products, including first-in-class (FIC) and best-in-class (BIC) therapies. The company's product portfolio spans key therapeutic areas such as cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology, and medical aesthetics. Key products include Plendil, Ursofalk, and various eye drops, among others. CMS employs a multi-platform strategy, encompassing in-house R&D, manufacturing services through PharmaGend, and market access in Southeast Asia via Rxilient Health. Its skin health business, Dermavon, has emerged as a leading entity in its field. [3, 6, 12, 18, 19, 21, 25, 27]

China Medical System Holdings Limited has been listed on the Main Board of the Stock Exchange of Hong Kong (HKEX:867) since September 2010 and was secondary listed on the Singapore Exchange (SGX:8A8) in July 2025. The company has recently seen its New Drug Application (NDA) for the seasonal allergic rhinitis indication of its innovative drug MG-K10 accepted in China in April 2026. CMS also secured an exclusive commercialization and supply agreement for intravenous iron products Monofer® and Cosmofer® in 2026 and has been included in the S&P Global Sustainability Yearbook (China Edition) for the fourth consecutive year. [1, 2, 5, 7, 14, 16, 18, 19, 20, 21, 22, 26]